JP2007514419A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007514419A5 JP2007514419A5 JP2006544041A JP2006544041A JP2007514419A5 JP 2007514419 A5 JP2007514419 A5 JP 2007514419A5 JP 2006544041 A JP2006544041 A JP 2006544041A JP 2006544041 A JP2006544041 A JP 2006544041A JP 2007514419 A5 JP2007514419 A5 JP 2007514419A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 44
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 30
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 30
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 30
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 30
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 29
- 239000000427 antigen Substances 0.000 claims 15
- 108091007433 antigens Proteins 0.000 claims 15
- 102000036639 antigens Human genes 0.000 claims 15
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 206010061218 Inflammation Diseases 0.000 claims 4
- 229940127121 immunoconjugate Drugs 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 238000012986 modification Methods 0.000 claims 4
- 230000004048 modification Effects 0.000 claims 4
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 3
- 208000036142 Viral infection Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 102000046438 human CXCL10 Human genes 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 210000004408 hybridoma Anatomy 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010001889 Alveolitis Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 101710112752 Cytotoxin Proteins 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims 1
- 101100222381 Homo sapiens CXCL11 gene Proteins 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 241000282560 Macaca mulatta Species 0.000 claims 1
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims 1
- 101000858054 Mus musculus C-X-C motif chemokine 10 Proteins 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 108700019146 Transgenes Proteins 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 230000006472 autoimmune response Effects 0.000 claims 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 230000009460 calcium influx Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000012292 cell migration Effects 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 102000051949 human CXCL9 Human genes 0.000 claims 1
- 230000028709 inflammatory response Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000011830 transgenic mouse model Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52918003P | 2003-12-10 | 2003-12-10 | |
| US60/529,180 | 2003-12-10 | ||
| PCT/US2004/041506 WO2005058815A2 (en) | 2003-12-10 | 2004-12-10 | Ip-10 antibodies and their uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011274263A Division JP5466691B2 (ja) | 2003-12-10 | 2011-12-15 | Ｉｐ−１０抗体およびその用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007514419A JP2007514419A (ja) | 2007-06-07 |
| JP2007514419A5 true JP2007514419A5 (https=) | 2007-12-27 |
| JP4942487B2 JP4942487B2 (ja) | 2012-05-30 |
Family
ID=34699950
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006544041A Expired - Fee Related JP4942487B2 (ja) | 2003-12-10 | 2004-12-10 | Ｉｐ−１０抗体およびその用途 |
| JP2011274263A Expired - Fee Related JP5466691B2 (ja) | 2003-12-10 | 2011-12-15 | Ｉｐ−１０抗体およびその用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011274263A Expired - Fee Related JP5466691B2 (ja) | 2003-12-10 | 2011-12-15 | Ｉｐ−１０抗体およびその用途 |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US20050191293A1 (https=) |
| EP (3) | EP2865687A1 (https=) |
| JP (2) | JP4942487B2 (https=) |
| KR (4) | KR20130133302A (https=) |
| CN (2) | CN1889979B (https=) |
| AU (1) | AU2004298492B2 (https=) |
| BR (1) | BRPI0417429A (https=) |
| CA (1) | CA2548338C (https=) |
| CY (2) | CY1113096T1 (https=) |
| DK (2) | DK1691837T3 (https=) |
| ES (2) | ES2388435T3 (https=) |
| HK (1) | HK1209759A1 (https=) |
| HR (2) | HRP20120702T1 (https=) |
| HU (1) | HUE025328T2 (https=) |
| IL (1) | IL175855A (https=) |
| MX (1) | MXPA06005941A (https=) |
| NO (1) | NO342278B1 (https=) |
| NZ (1) | NZ547499A (https=) |
| PL (2) | PL1691837T3 (https=) |
| PT (2) | PT1691837E (https=) |
| RS (1) | RS53984B1 (https=) |
| RU (1) | RU2486199C2 (https=) |
| SI (2) | SI1691837T1 (https=) |
| WO (1) | WO2005058815A2 (https=) |
| ZA (1) | ZA200604620B (https=) |
Families Citing this family (127)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| US8597911B2 (en) * | 2003-06-11 | 2013-12-03 | Chugai Seiyaku Kabushiki Kaisha | Process for producing antibodies |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| RS53984B1 (sr) * | 2003-12-10 | 2015-10-30 | E. R. Squibb & Sons L.L.C. | Ip-10 antitela i njihove upotrebe |
| LT2857418T (lt) * | 2004-02-06 | 2017-09-25 | University Of Massachusetts | Antikūnai prieš clostridium difficile toksinus ir jų panaudojimas |
| TW200714610A (en) | 2005-02-16 | 2007-04-16 | Univ Maryland | CXCR3 is a gliadin receptor |
| EP3050963B1 (en) * | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| CA2623236A1 (en) | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Human monoclonal antibodies to cd70 |
| RU2432362C2 (ru) | 2005-11-30 | 2011-10-27 | Эбботт Лэборетриз | Моноклональные антитела и их применения |
| PL2289909T3 (pl) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał |
| AU2013200177B2 (en) * | 2005-11-30 | 2014-10-02 | Abbvie Deutschland Gmbh & Co Kg | Monoclonal antibodies against amyloid beta protein and uses thereof |
| US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
| ES2892925T3 (es) * | 2006-03-31 | 2022-02-07 | Chugai Pharmaceutical Co Ltd | Métodos para controlar la farmacocinética en sangre de anticuerpos |
| MX2009002418A (es) | 2006-09-05 | 2009-04-23 | Medarex Inc | Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso. |
| US8178100B2 (en) | 2006-10-13 | 2012-05-15 | Seoul National University Industry Foundation | Antibodies to IP-10 for treating bone diseases with bone destruction |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| KR20090088946A (ko) * | 2006-12-14 | 2009-08-20 | 메다렉스, 인코포레이티드 | 씨디70에 결합하는 인간 항체 및 이의 용도 |
| US20110044945A1 (en) * | 2007-02-08 | 2011-02-24 | Rappaport Family Institute For Research In The Medical Sciences | Agents for the treatment of multiple sclerosis and methods of using same |
| EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
| CN101668774B (zh) * | 2007-02-28 | 2013-06-26 | 诺维莫尼公司 | 抗干扰素诱导蛋白-10的抗体及其使用方法 |
| US8263064B2 (en) | 2007-06-04 | 2012-09-11 | Rappaport Family Institute For Research In The Medical Sciences | Method of suppressing disease severity of multiple sclerosis using chemokine CXC11 |
| WO2009097006A2 (en) * | 2007-08-10 | 2009-08-06 | Medarex, Inc. | Hco32 and hco27 and related examples |
| WO2009026660A1 (en) * | 2007-08-30 | 2009-03-05 | Walter And Eliza Hall Institute Of Medical Research | Dendritic cell marker and uses thereof |
| AU2008304748C1 (en) | 2007-09-26 | 2014-06-12 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| CA2700860C (en) * | 2007-10-01 | 2016-07-19 | Jonathan A. Terrett | Human antibodies that bind mesothelin, and uses thereof |
| DK2851374T3 (en) | 2007-12-14 | 2017-06-19 | Bristol Myers Squibb Co | Binding molecules to the human OX40 receptor |
| WO2009083009A2 (en) * | 2008-01-03 | 2009-07-09 | Genmab A/S | Monoclonal antibodies against cd32b |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| EP2346994B1 (en) | 2008-09-30 | 2022-02-16 | Ablexis, LLC | Knock-in mice for the production of chimeric antibodies |
| UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
| WO2010103517A1 (en) | 2009-03-12 | 2010-09-16 | Rappaport Family Institute For Research In The Medical Sciences | Soluble compositions for the treatment of cxcr3-ligand associated diseases |
| TWI682995B (zh) | 2009-03-19 | 2020-01-21 | 日商中外製藥股份有限公司 | 抗體恆定區域改變體 |
| WO2010107110A1 (ja) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | 抗体定常領域改変体 |
| WO2010129351A1 (en) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Method to identify and treat age-related macular degeneration |
| PL2248825T3 (pl) * | 2009-05-04 | 2013-04-30 | Ribovax Biotechnologies Sa | Fragmenty przeciwciała wiążące antygen do zastosowania w leczeniu i diagnozowaniu chorób oczu |
| BR112012000536A2 (pt) | 2009-07-08 | 2020-08-11 | Kymab Limited | métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico |
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
| JP5889181B2 (ja) | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | 抗体定常領域改変体 |
| EP3511342B1 (en) | 2010-03-10 | 2024-01-17 | Genmab A/S | Monoclonal antibodies against c-met |
| KR102203727B1 (ko) | 2010-03-31 | 2021-01-18 | 아블렉시스, 엘엘씨 | 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작 |
| ES2684475T3 (es) | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteínas que se unen a beta amiloide |
| JP6055404B2 (ja) | 2010-06-15 | 2016-12-27 | ゲンマブ エー／エス | 組織因子に対するヒト抗体薬物結合体 |
| CN103298833B (zh) | 2010-08-14 | 2015-12-16 | Abbvie公司 | β淀粉样蛋白结合蛋白 |
| PH12016502073B1 (en) | 2010-11-17 | 2024-04-05 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
| RS67768B1 (sr) | 2010-11-30 | 2026-03-31 | Chugai Pharmaceutical Co Ltd | Terapijski agens koji indukuje citotoksičnost |
| TWI812066B (zh) | 2010-11-30 | 2023-08-11 | 日商中外製藥股份有限公司 | 具有鈣依存性的抗原結合能力之抗體 |
| CN102161982B (zh) * | 2011-03-09 | 2012-12-26 | 苏州大学 | 抗人cxcr3分子单抗及其应用 |
| MX2013012284A (es) | 2011-04-29 | 2013-11-21 | Bristol Myers Squibb Co | Regimenes de elevacion de dosis del anticuerpo de proteina 10 inducible por interferon gamma (ip-10). |
| BR112014006394A2 (pt) | 2011-09-19 | 2017-03-28 | Kymab Ltd | manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos |
| WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| JP5963233B2 (ja) * | 2011-12-07 | 2016-08-03 | 学校法人 聖マリアンナ医科大学 | Ｈｔｌｖ−１関連脊髄症を治療または予防するための医薬および前記医薬を用いた抗体療法の治療効果の確認方法 |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| CN103417967B (zh) * | 2012-05-15 | 2017-05-10 | 中国医学科学院基础医学研究所 | Cxcl‑10抑制剂在制备治疗和/或预防肺损伤的药物中的用途 |
| PL3489261T3 (pl) | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| KR101452865B1 (ko) * | 2012-09-17 | 2014-10-21 | 서울대학교산학협력단 | 신규한 ｉｐ－１０ 에피토프 및 이에 대한 항체 |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| JP6534615B2 (ja) | 2013-09-27 | 2019-06-26 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| DE112014004537T5 (de) | 2013-10-01 | 2016-07-21 | Kymab Limited | Tiermodelle und therapeutische Moleküle |
| SI3227339T1 (sl) * | 2014-12-05 | 2022-02-28 | Memorial Sloan-Kettering Cancer Center | Himerni antigenski receptorji, ki ciljajo na receptor, povezan z G-proteinom, in njihova uporaba |
| JP6676058B2 (ja) | 2015-01-14 | 2020-04-08 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ヘテロアリーレン架橋したベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法 |
| JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| KR102876923B1 (ko) * | 2015-10-23 | 2025-10-28 | 화이자 인코포레이티드 | 항-il-2 항체 및 조성물 및 이의 용도 |
| CN108350416A (zh) | 2015-11-09 | 2018-07-31 | 百时美施贵宝公司 | 操纵在cho细胞中产生的多肽的品质属性的方法 |
| WO2017095875A1 (en) | 2015-11-30 | 2017-06-08 | Bristol-Myers Squibb Company | Anti human ip-10 antibodies and their uses |
| AU2016377371A1 (en) | 2015-12-21 | 2018-08-09 | Bristol-Myers Squibb Company | Variant antibodies for site-specific conjugation |
| CN108368166B (zh) | 2015-12-28 | 2023-03-28 | 中外制药株式会社 | 提高含fc区多肽纯化效率的方法 |
| MA44780A (fr) | 2016-04-28 | 2019-03-06 | Chugai Pharmaceutical Co Ltd | Préparation contenant un anticorps |
| KR20190005924A (ko) | 2016-05-10 | 2019-01-16 | 브리스톨-마이어스 스큅 컴퍼니 | 향상된 안정성을 갖는 튜부리신 유사체의 항체-약물 접합체 |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| IL299099B2 (en) | 2016-06-27 | 2025-07-01 | Univ California | Cancer treatment combinations |
| CN109641911B (zh) | 2016-08-19 | 2023-02-21 | 百时美施贵宝公司 | seco-环丙吡咯并吲哚化合物和其抗体-药物缀合物以及制备和使用方法 |
| FI4050034T3 (fi) * | 2016-09-14 | 2024-06-10 | Teneoone Inc | Cd3:een sitoutuvia vasta-aineita |
| US10398783B2 (en) | 2016-10-20 | 2019-09-03 | Bristol-Myers Squibb Company | Antiproliferative compounds and conjugates made therefrom |
| WO2018097308A1 (ja) | 2016-11-28 | 2018-05-31 | 中外製薬株式会社 | リガンド結合活性が調整可能なリガンド結合分子 |
| US10610104B2 (en) | 2016-12-07 | 2020-04-07 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| NZ754713A (en) | 2016-12-21 | 2025-11-28 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
| CN110461358A (zh) | 2017-03-31 | 2019-11-15 | 公立大学法人奈良县立医科大学 | 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物 |
| EP3635097A1 (en) | 2017-06-05 | 2020-04-15 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
| US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
| US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
| US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
| US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
| US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
| US11698358B2 (en) | 2017-09-07 | 2023-07-11 | Bristol-Myers Squibb Company | Method of purity determination by capillary electrophoresis |
| CN107656067B (zh) * | 2017-09-18 | 2019-11-15 | 上海交通大学医学院附属上海儿童医学中心 | 一种评估sle患儿总体疾病活动度和肾脏疾病活动度的检测方法及其应用 |
| AU2018361430B2 (en) | 2017-11-01 | 2025-08-14 | Chugai Seiyaku Kabushiki Kaisha | Antibody variant and isoform with lowered biological activity |
| CN111630062A (zh) | 2017-11-28 | 2020-09-04 | 中外制药株式会社 | 具有可调节的配体结合活性的配体结合分子 |
| CN111836828B (zh) | 2017-11-28 | 2024-12-20 | 中外制药株式会社 | 包括抗原结合结构域和运送部分的多肽 |
| GB201803892D0 (en) | 2018-03-12 | 2018-04-25 | Ultrahuman Six Ltd | C-met binding agents |
| CN108531460B (zh) * | 2018-03-30 | 2020-07-14 | 四川迈克生物新材料技术有限公司 | 抗人IgM单克隆抗体、其杂交瘤细胞株及应用 |
| WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
| WO2019217457A1 (en) | 2018-05-07 | 2019-11-14 | Genmab A/S | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
| WO2019217455A1 (en) | 2018-05-07 | 2019-11-14 | Genmab A/S | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
| CN112188902A (zh) | 2018-05-29 | 2021-01-05 | 百时美施贵宝公司 | 用于前药和缀合物的经修饰的自消灭部分以及使用和制造方法 |
| US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| US20220249814A1 (en) | 2018-11-19 | 2022-08-11 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| CN111228491B (zh) * | 2018-11-29 | 2022-07-01 | 中国人民解放军军事科学院军事医学研究院 | Ip-10抑制剂在预防和/或治疗寨卡病毒感染中的应用 |
| ES2943474T3 (es) | 2018-11-30 | 2023-06-13 | Bristol Myers Squibb Co | Anticuerpo que comprende una extensión carboxiterminal de una cadena ligera que contiene glutamina, conjugados del mismo, y métodos y usos |
| KR20210102334A (ko) | 2018-12-12 | 2021-08-19 | 브리스톨-마이어스 스큅 컴퍼니 | 트랜스글루타미나제 접합을 위해 변형된 항체, 그의 접합체, 및 방법 및 용도 |
| GB201820554D0 (en) * | 2018-12-17 | 2019-01-30 | Univ Oxford Innovation Ltd | BTLA antibodies |
| JP7776987B2 (ja) | 2019-04-05 | 2025-11-27 | テネオバイオ， インコーポレイテッド | Ｐｓｍａに結合する重鎖抗体 |
| CN114206927B (zh) | 2019-06-14 | 2025-03-21 | 特尼奥生物股份有限公司 | 与cd22和cd3结合的多特异性重链抗体 |
| WO2021055306A1 (en) | 2019-09-16 | 2021-03-25 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
| CA3154648A1 (en) * | 2019-09-16 | 2021-03-25 | Opsidio, LLC | Anti-stem cell factor antibodies and methods of use thereof |
| EP4051318A4 (en) * | 2019-10-29 | 2023-10-11 | International AIDS Vaccine Initiative | ENGINEERED ANTI-ENV HIV ANTIBODIES |
| AU2020379001A1 (en) | 2019-11-04 | 2022-06-09 | Paul RUBINSTEIN | Anti-CD30 antibody-drug conjugates and their use for the treatment of HIV infection |
| TW202131954A (zh) | 2019-11-07 | 2021-09-01 | 丹麥商珍美寶股份有限公司 | 利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法 |
| MX2022005222A (es) | 2019-11-07 | 2022-06-08 | Genmab As | Metodos para tratar el cancer con una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y un conjugado de anticuerpo anti factor tisular-farmaco. |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| MX2022015375A (es) | 2020-06-29 | 2023-01-16 | Genmab As | Conjugados de farmaco-anticuerpo anti-factor de tejido y su uso en el tratamiento de cancer. |
| WO2022108931A2 (en) | 2020-11-17 | 2022-05-27 | Seagen Inc. | Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody |
| CN113603773B (zh) * | 2021-08-17 | 2023-05-09 | 中国医科大学附属第一医院 | 靶向淀粉样蛋白的单克隆抗体7b8、分泌该抗体的杂交瘤细胞株及应用 |
| IL312110A (en) | 2021-10-29 | 2024-06-01 | Seagen Inc | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate |
| CN114656561B (zh) * | 2022-03-05 | 2023-06-09 | 南京鼓楼医院 | 一种抗ip-10单克隆抗体 |
| WO2023213960A1 (en) | 2022-05-06 | 2023-11-09 | Genmab A/S | Methods of treating cancer with anti-tissue factor antibody-drug conjugates |
| WO2024256527A1 (en) | 2023-06-13 | 2024-12-19 | Institut National de la Santé et de la Recherche Médicale | Use of a cxcl 10 inhibitor for the treatment of transplant vasculopathy |
| WO2025188693A1 (en) | 2024-03-05 | 2025-09-12 | Bristol-Myers Squibb Company | Bicyclic tlr7 agonists and uses thereof |
| WO2025188694A1 (en) | 2024-03-05 | 2025-09-12 | Bristol-Myers Squibb Company | Tricyclic tlr7 agonists and uses thereof |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4954617A (en) | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| DE69027121T3 (de) * | 1989-08-07 | 2001-08-30 | Peptech Ltd., Dee Why | Bindeligande für tumornekrosisfaktor |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US7084260B1 (en) * | 1996-10-10 | 2006-08-01 | Genpharm International, Inc. | High affinity human antibodies and human antibodies against human antigens |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
| CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| GB9621295D0 (en) * | 1995-12-07 | 1996-11-27 | Cambridge Antibody Tech | Specific binding members,materials and methods |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| US6177545B1 (en) * | 1997-09-02 | 2001-01-23 | Insight Strategy & Marketing Ltd. | Heparanase specific molecular probes and their use in research and medical applications |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| CA2360019A1 (en) * | 1999-01-29 | 2000-08-03 | Shixin Qin | Anti-ccr1 antibodies and methods of use therefor |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| DE60037896D1 (de) | 1999-07-29 | 2008-03-13 | Medarex Inc | Menschliche antikörper gegen her2/neu |
| JP3585399B2 (ja) * | 1999-07-30 | 2004-11-04 | 独立行政法人 科学技術振興機構 | 抗マウスｔｒａｉｌモノクローナル抗体 |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| US6652854B2 (en) * | 2000-08-08 | 2003-11-25 | Immunex Corporation | Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
| AU8828601A (en) * | 2000-08-18 | 2002-03-04 | Univ California | Methods for treating demyelinating diseases |
| CN1487996B (zh) | 2000-11-30 | 2010-06-16 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
| EP1421203A4 (en) | 2001-05-17 | 2005-06-01 | Diversa Corp | NEW ANTIGEN-BINDING MOLECULES FOR THERAPEUTIC, DIAGNOSTIC, PROPHYLACTIC, ENZYMATIC, INDUSTRIAL AND AGRICULTURAL APPLICATIONS AND METHOD FOR THE PRODUCTION AND SCREENING THEREOF |
| US20030166589A1 (en) * | 2001-06-05 | 2003-09-04 | Nathan Karin | Method and pharmaceutical composition for the treatment of multiple sclerosis |
| JP2005501036A (ja) | 2001-07-12 | 2005-01-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 二次的な組織変性のｃｘｃｌ１０処置 |
| US20040096446A1 (en) | 2001-08-17 | 2004-05-20 | Lane Thomas E. | Methods for treating demyelinating diseases |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| US7442512B2 (en) * | 2001-11-30 | 2008-10-28 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| BR0307216A (pt) * | 2002-01-28 | 2005-12-20 | Medarex Inc | Anticorpos monoclonais humanos para antìgeno de membrana especìfica de próstata (psma) |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| SI1916001T1 (sl) * | 2002-03-04 | 2011-10-28 | Imclone Llc | Äśloveĺ ka protitelesa specifiäśna za kdr in njihova uporaba |
| AU2003294290A1 (en) * | 2002-11-15 | 2004-06-15 | Morehouse School Of Medicine | Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation. |
| WO2004101511A2 (en) * | 2003-05-09 | 2004-11-25 | Protein Design Labs, Inc | Anti-ip-10 antibodies and methods of using thereof for the treatment of inflamatory bowel diseases |
| ATE501173T1 (de) * | 2003-12-04 | 2011-03-15 | Abbott Biotherapeutics Corp | Anti-ip-10-antikörper |
| RS53984B1 (sr) | 2003-12-10 | 2015-10-30 | E. R. Squibb & Sons L.L.C. | Ip-10 antitela i njihove upotrebe |
| CN101668774B (zh) * | 2007-02-28 | 2013-06-26 | 诺维莫尼公司 | 抗干扰素诱导蛋白-10的抗体及其使用方法 |
| MX2013012284A (es) | 2011-04-29 | 2013-11-21 | Bristol Myers Squibb Co | Regimenes de elevacion de dosis del anticuerpo de proteina 10 inducible por interferon gamma (ip-10). |
-
2004
- 2004-12-10 RS RS20150285A patent/RS53984B1/sr unknown
- 2004-12-10 CN CN2004800368431A patent/CN1889979B/zh not_active Expired - Fee Related
- 2004-12-10 KR KR1020137029040A patent/KR20130133302A/ko not_active Ceased
- 2004-12-10 CN CN201210260781.9A patent/CN102838675B/zh not_active Expired - Fee Related
- 2004-12-10 ES ES04813771T patent/ES2388435T3/es not_active Expired - Lifetime
- 2004-12-10 DK DK04813771.5T patent/DK1691837T3/da active
- 2004-12-10 JP JP2006544041A patent/JP4942487B2/ja not_active Expired - Fee Related
- 2004-12-10 CA CA2548338A patent/CA2548338C/en not_active Expired - Fee Related
- 2004-12-10 WO PCT/US2004/041506 patent/WO2005058815A2/en not_active Ceased
- 2004-12-10 EP EP20140191352 patent/EP2865687A1/en not_active Withdrawn
- 2004-12-10 HR HRP20120702TT patent/HRP20120702T1/hr unknown
- 2004-12-10 PT PT04813771T patent/PT1691837E/pt unknown
- 2004-12-10 AU AU2004298492A patent/AU2004298492B2/en not_active Ceased
- 2004-12-10 EP EP20110166104 patent/EP2383295B1/en not_active Expired - Lifetime
- 2004-12-10 US US11/009,731 patent/US20050191293A1/en not_active Abandoned
- 2004-12-10 KR KR1020127005738A patent/KR101333449B1/ko not_active Expired - Fee Related
- 2004-12-10 NZ NZ547499A patent/NZ547499A/en not_active IP Right Cessation
- 2004-12-10 KR KR1020127033449A patent/KR101374514B1/ko not_active Expired - Fee Related
- 2004-12-10 PL PL04813771T patent/PL1691837T3/pl unknown
- 2004-12-10 PL PL11166104T patent/PL2383295T3/pl unknown
- 2004-12-10 EP EP04813771A patent/EP1691837B1/en not_active Expired - Lifetime
- 2004-12-10 ZA ZA200604620A patent/ZA200604620B/en unknown
- 2004-12-10 SI SI200431929T patent/SI1691837T1/sl unknown
- 2004-12-10 DK DK11166104.7T patent/DK2383295T3/en active
- 2004-12-10 ES ES11166104.7T patent/ES2537163T3/es not_active Expired - Lifetime
- 2004-12-10 KR KR1020067013685A patent/KR20060135690A/ko not_active Ceased
- 2004-12-10 MX MXPA06005941A patent/MXPA06005941A/es active IP Right Grant
- 2004-12-10 PT PT111661047T patent/PT2383295E/pt unknown
- 2004-12-10 HU HUE11166104A patent/HUE025328T2/en unknown
- 2004-12-10 BR BRPI0417429-1A patent/BRPI0417429A/pt not_active IP Right Cessation
- 2004-12-10 RU RU2006124611/10A patent/RU2486199C2/ru not_active IP Right Cessation
- 2004-12-10 SI SI200432240T patent/SI2383295T1/sl unknown
-
2006
- 2006-05-23 IL IL175855A patent/IL175855A/en not_active IP Right Cessation
- 2006-06-08 NO NO20062630A patent/NO342278B1/no not_active IP Right Cessation
-
2009
- 2009-05-27 US US12/472,877 patent/US8258266B2/en not_active Expired - Lifetime
-
2011
- 2011-12-15 JP JP2011274263A patent/JP5466691B2/ja not_active Expired - Fee Related
-
2012
- 2012-05-23 US US13/478,786 patent/US8945546B2/en not_active Expired - Lifetime
- 2012-09-05 CY CY20121100802T patent/CY1113096T1/el unknown
-
2014
- 2014-12-22 US US14/579,156 patent/US9994633B2/en active Active
-
2015
- 2015-04-20 HR HRP20150429TT patent/HRP20150429T1/hr unknown
- 2015-06-05 CY CY20151100500T patent/CY1116364T1/el unknown
- 2015-10-20 HK HK15110321.2A patent/HK1209759A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007514419A5 (https=) | ||
| JP2012100667A5 (https=) | ||
| HRP20150429T1 (hr) | Ip-10 antitijela i njihove uporabe | |
| JP2008508864A5 (https=) | ||
| JP7304320B2 (ja) | 抗Ｐｒｅ－Ｓ１ ＨＢＶ抗体 | |
| RU2009128064A (ru) | Антитела к cd44 | |
| RU2007102079A (ru) | Антитела рецептора интерферона альфа и их применение | |
| JP2010511388A5 (https=) | ||
| JP2010500005A5 (https=) | ||
| JP2020513791A5 (https=) | ||
| JP2019511911A5 (https=) | ||
| JP2008516970A5 (https=) | ||
| WO2014058924A2 (en) | Antibodies recognizing alpha-synuclein | |
| JP2014500009A5 (https=) | ||
| JP2020501550A5 (https=) | ||
| JP2012501670A5 (https=) | ||
| JP2018500014A5 (https=) | ||
| JP2012501669A5 (https=) | ||
| JP2006505277A5 (https=) | ||
| JP2012500020A5 (https=) | ||
| JP2019522961A5 (https=) | ||
| CN101512008A (zh) | 白介素-13结合蛋白 | |
| JP2019527194A5 (https=) | ||
| JP2010511056A5 (https=) | ||
| EP2807188A1 (en) | Humanized antibodies that recognize alpha-synuclein |